ï»¿<!DOCTYPE html ><html><body><div>H-0883.2</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><div style="font-weight:bold;text-align:center;">HOUSE BILL 1741</div><hr style="margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;" /><table style="width:622px;margin-top:0.1in;"><tr><td><div style="font-weight:bold;">State of Washington</div></td><td><div style="font-weight:bold;">69th Legislature</div></td><td><div style="font-weight:bold;">2025 Regular Session</div></td></tr></table><div style="margin-top:0.1in;"><span style="font-weight:bold;margin-right:0.25in;">By</span><!-- field: Sponsors -->Representatives Thai, Leavitt, Paul, Simmons, Couture, Parshley, Fey, Duerr, Nance, and Davis<!-- field: --></div><div style="margin-top:0.1in;"><span style="margin-right:0.25in;">Read first time 01/30/25.</span><span style="margin-right:0.25in;">Referred to Committee on Health Care &amp; Wellness.</span></div><div style="text-indent:0.5in;margin-top:0.5in;"><!-- field: CaptionsTitles -->AN ACT Relating to expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome; and adding a new section to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW.<!-- field: --></div><div style="margin-top:0.25in;margin-bottom:0.25in;">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style="margin-top:0.25in;text-indent:0.5in;"><!-- field: BeginningSection --><span style="text-decoration:underline;">NEW SECTION.</span><span>Â Â </span><span style="font-weight:bold;padding-right:0.1in;">Sec. 1.  </span>A new section is added to chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=48.43'>48.43</a> RCW to read as follows:<!-- field: --></div><div style="text-indent:0.5in;"><!-- field: Text -->(1) For health plans other than health plans offered to public employees and dependents under chapter  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=41.05'>41.05</a> RCW issued or renewed on or after January 1, 2026, health carriers shall provide initial coverage of three monthly immunomodulatory courses of intravenous immunoglobulin therapy for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome, and subsequent courses as deemed medically necessary by the treating provider, when the following conditions are met:</div><div style="text-indent:0.5in;">(a) Clinically appropriate trials, which may be done concurrently, of two or more less intensive treatments were:</div><div style="text-indent:0.5in;">(i) Not effective;</div><div style="text-indent:0.5in;">(ii) Not tolerated; or</div><div style="text-indent:0.5in;">(iii) Did not result in sustained improvement in symptoms, as measured by a lack of clinically meaningful improvement on a validated instrument directed at the patient's primary symptom complex; and</div><div style="text-indent:0.5in;">(b) A pediatric subspecialist is consulted and the pediatric subspecialist and the patient's primary care provider recommend the treatment. For an adolescent or adult patient, the consultation may be with an adult subspecialist. The subspecialist consultation may be a teleconsultation.</div><div style="text-indent:0.5in;">(2) The health carrier may require that the patient be clinically reevaluated at three-month intervals.</div><!-- field: --><div style="margin-top:0.1in;font-weight:bold;text-align:center;">--- END ---</div></body></html>